2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or …
In 2014, a joint consensus document dealing with the management of antithrombotic therapy
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …
Combination lipid-lowering therapy as first-line strategy in very high-risk patients
When diet and lifestyle are insufficient to attenuate the risk of atherosclerotic cardiovascular
disease, pharmacotherapy is mandated. A global approach that addresses multiple risk …
disease, pharmacotherapy is mandated. A global approach that addresses multiple risk …
Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial
D Fitchett, SE Inzucchi, CP Cannon, DK McGuire… - Circulation, 2019 - Am Heart Assoc
Background: In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular
Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes …
Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes …
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European …
Task Force Members, G Montalescot… - European heart …, 2013 - academic.oup.com
Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …
is recommended in the guidelines, thus completing the loop between clinical research …
[HTML][HTML] Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement
Risk for atherosclerotic cardiovascular disease (ASCVD) shows considerable heterogeneity
both in generally healthy persons and in those with known ASCVD. The foundation of …
both in generally healthy persons and in those with known ASCVD. The foundation of …
Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease
Importance Precise stratification of cardiovascular risk in patients with coronary heart
disease (CHD) is needed to inform treatment decisions. Objective To derive and validate a …
disease (CHD) is needed to inform treatment decisions. Objective To derive and validate a …
The myth of 'stable'coronary artery disease
Patients with known cardiovascular disease who have not had a recent acute event are
often referred to as having stable coronary artery disease (CAD). The concept of 'stable'CAD …
often referred to as having stable coronary artery disease (CAD). The concept of 'stable'CAD …
Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population
L Kaasenbrood, SM Boekholdt, Y Van Der Graaf… - Circulation, 2016 - Am Heart Assoc
Background: Among patients with clinically manifest vascular disease, the risk of recurrent
vascular events is likely to vary. We assessed the distribution of estimated 10-year risk of …
vascular events is likely to vary. We assessed the distribution of estimated 10-year risk of …
Coronary 18F-Sodium Fluoride Uptake Predicts Outcomes in Patients With Coronary Artery Disease
Background Reliable methods for predicting myocardial infarction in patients with
established coronary artery disease are lacking. Coronary 18F-sodium fluoride (18F-NaF) …
established coronary artery disease are lacking. Coronary 18F-sodium fluoride (18F-NaF) …